10x Genomics vs Veracyte
10x Genomics is the larger business, with $643m of revenue in fiscal 2025 against $517m for Veracyte (1.2 times as much). Veracyte grew faster (16.0% against 5.2%). Veracyte kept more of each dollar of sales as profit: a net margin of 12.8% against -6.8%. 10x Genomics carries less debt relative to equity (0.0% against 0.0%).
| Latest fiscal year | 10x GenomicsTXG, 2025 | VeracyteVCYT, 2025 |
|---|---|---|
| Revenue | $643m | $517m |
| Revenue growth | 5.2% | 16.0% |
| Net income | −$43.5m | $66.4m |
| Operating margin | -9.5% | 11.2% |
| Net margin | -6.8% | 12.8% |
| Return on equity | -5.8% | 5.3% |
| Free cash flow | $130m | $127m |
| Cash | $474m | $363m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | 0.0% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 755 |
| Market value | $8.34bn | $4.04bn |
| Price vs our value range | — | Above our value range |
| Moat score | 33 (Weak) | 14 (Weak) |
| Insider trades, 12 months | 0 buys, 50 sales | 0 buys, 61 sales |